Meet OPLE, our DiscoveryAI™ application to predict the likelihood of activity of small molecules against SafetyScreen targets to enable faster, more reliable drug development. Trained with high-quality Eurofins Discovery proprietary data, OPLE harnesses molecular similarity and machine learning to identify potential safety risks early, reducing time and costs at each drug discovery phase. Use OPLE to make informed, data-driven decisions that bring your molecules to market quicker with greater confidence.
Unlock the Power of Predictive AI for Drug Safety
In the dynamic realm of artificial intelligence, data quality stands as the linchpin determining the success or failure of machine learning models. Predictive models are only as strong as the data used to train them. OPLE models are trained with high-quality EMERALD data featuring proprietary and expertly curated publicly available data. EMERALD datasets are built from rigorous testing in Eurofins’ premier assay laboratories on compounds of interest that Eurofins has independently sourced and purchased. The OPLE platform trained with EMERALD data empowers accelerated drug discovery with unparalleled reliability and ease-of-use.
OPLE currently includes models for targets on SafetyScreen18 and SafetyScreen44 panels. In addition to predicting the percentage likelihood of activity against SafetyScreen targets, OPLE also reports the most similar known active compound for each input. Users can also set their own applicability domain similarity threshold to guide insights.
